Krystal Biotech Reports Q1 Earnings with Strong Revenue and Guidance
Krystal Biotech reported $116.4 million in first-quarter net revenue from VYJUVEK, driven by strong U.S. sales and early international traction. The company maintained a 95% gross margin and ended the quarter with over $1 billion in cash while reaffirming its full-year non-GAAP operating expense guidance of $175–$195 million.
Tickers: $KRYS
Topics: biotech clinical pipeline financial performance pharmaceuticals